Pfizer Global Research news from FierceBiotech
News
C&L: Una Ryan leaves Avant
Avant Immunotherapeutics today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Watson Pharmaceuticals announced that co-founder and Chairman Allen Chao has Read more...
Pfizer spins off Esperion as VCs ante up $22.75M
Pfizer has spun of Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold Read more...
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more Read more...
Pfizer, Adolor ink pain drug deal
Continuing on its deal-making quest, Pfizer has signed an agreement with Exton, PA-based Adolor for ADL5859 and ADL5747. The two pain drugs Read more...
Pfizer, Hydra strike $195M pain pact
Cambridge, MA-based Hydra Biosciences has struck a deal with Pfizer Global Research & Development to collaborate on new pain therapies. Hydra stands to gain up to $195 million in up front and Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets